Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Medical Research Council
Headquarters: London, United Kingdom
Website: http://www.mrc.ac.uk
Year Founded: 1919
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Aug 8, 2024
Discovery & Translation
Science Spotlight: Stopping herpes from entering neurons, tissue-specific nanoparticles, and more
BioCentury’s roundup of translational innovations
BioCentury | Oct 20, 2023
Discovery & Translation
The emerging base editor toolkit
A deep dive into how academics and biotechs are expanding the therapeutic potential of base editors by iterating on the tech’s three major types
BioCentury | May 26, 2023
Politics, Policy & Law
U.K. £650M financing package includes major boost for UK Biobank
Financing policies include streamlined trial approvals, investment vehicles for pensions
BioCentury | Jun 20, 2022
Deals
U.K. partners to accelerate gene therapy development for dementia
CGT Catapult, UK DRI to work with academic centers to identify assets
BioCentury | Mar 10, 2022
Product Development
Global mRNA, biologics manufacturing gaining momentum
WHO backing mRNA vaccine capacity, Korea providing a global biomanufacturing training center
BioCentury | Oct 29, 2021
Product Development
Bicycle Therapeutics on a roll
Bicycle is planning to parlay clinical proof of concept for its bicyclic-toxin conjugates into new technologies and product deals
BioCentury | Mar 5, 2021
Product Development
March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more
The ACCESS consortium, a coalition of regulatory authorities from the U.K., Australia, Canada, Singapore and Switzerland, released guidance on Thursday outlining the data needed to approve
BioCentury | Oct 17, 2020
Translation in Brief
SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more
BioCentury’s roundup of translational news
BioCentury | Apr 4, 2020
Product Development
U.K. government backs Oxford’s adaptive trial for COVID-19
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Oct 14, 2019
Financial News
Mogrify raises $16M, outlines plans to advance cell therapy platform
Items per page:
1 - 10 of 313